-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 Rqn1rSReUnH7B8yApi6mjP93MOS96JBEEs1bUkbsx5mtWgpQPDkMW2himxJEEKdp
 c1H4Gwaoa5VZBTcCnfYTMw==

<SEC-DOCUMENT>0001075880-09-000023.txt : 20090414
<SEC-HEADER>0001075880-09-000023.hdr.sgml : 20090414
<ACCEPTANCE-DATETIME>20090414083204
ACCESSION NUMBER:		0001075880-09-000023
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20090414
FILED AS OF DATE:		20090414
DATE AS OF CHANGE:		20090414

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NOVOGEN LTD
		CENTRAL INDEX KEY:			0001075880
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-29962
		FILM NUMBER:		09747678

	BUSINESS ADDRESS:	
		STREET 1:		140 WICKS RD
		STREET 2:		NORTH RYDE
		CITY:			NEW SOUTH WALES 2113
		STATE:			C3
		ZIP:			2113
		BUSINESS PHONE:		01161298780088

	MAIL ADDRESS:	
		STREET 1:		107 NORTH RYDE
		CITY:			SYDNEY
		STATE:			C3
		ZIP:			1670
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>form6k20090414.htm
<DESCRIPTION>FORM 6K 2009 04 14
<TEXT>
<html>
  <head>
    <title>form6k20090414.htm</title>
<!-- Licensed to: Novogen Laboratories Pty Ltd-->
<!-- Document Created using EDGARizer 4.0.7.0 -->
<!-- Copyright 1995 - 2008 EDGARfilings, Ltd., an IEC company. All rights reserved -->
</head>
    <body bgcolor="#ffffff" style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 5%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 5%; FONT-FAMILY: Times New Roman">
    <div>
      <hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="4">
      <hr style="MARGIN-TOP: -10px; COLOR: #000000" noshade size="1">
    </div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 36pt; FONT-FAMILY: Times New Roman">UNITED
STATES</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 36pt; FONT-FAMILY: Times New Roman">SECURITIES
AND EXCHANGE COMMISSION</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 18pt; FONT-FAMILY: Times New Roman">Washington,
D.C. 20549</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman">______________________________________________</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 18pt; FONT-FAMILY: Times New Roman">Form
6-K</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 18pt; FONT-FAMILY: Times New Roman">REPORT
OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER
THE</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 18pt; FONT-FAMILY: Times New Roman">SECURITIES
EXCHANGE ACT OF 1934</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">For the
month of April, 2009</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">Commission
File Number <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">________________</font></font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 36pt; FONT-FAMILY: Times New Roman">Novogen
Limited</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">(Translation
of registrant&#8217;s name into English)</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 18pt; FONT-FAMILY: Times New Roman">140 Wicks
Road, North Ryde, NSW, Australia</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman">(Address
of principal executive office)</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman">___________________________________</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">Indicate
by check mark whether the registrant files or will file annual reports under
cover of Form 20-F or Form 40-F.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">Form 20-F
<font style="DISPLAY: inline; FONT-WEIGHT: bold;" face="Wingdings">x</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>Form 40-F <font style="DISPLAY: inline; FONT-WEIGHT: bold;" face="Wingdings">o</font></font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted
by Regulation S-T Rule 101(b)(l):<font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold;" face="Wingdings">o</font></font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">Note:
Regulation S-T Rule 101 (b)( I) only permits the submission in paper of a Form
6-K if submitted solely to provide an attached annual report to security
holders.</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted
by Regulation S-T Rule lO1(b)(7): <font style="DISPLAY: inline; FONT-WEIGHT: bold;" face="Wingdings">o</font></font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">Note:
Regulation S-T Rule l01(b)(7) only permits the submission in paper of a Form 6-K
if submitted to furnish a report or other document that the registrant foreign
private issuer must furnish and make public under the laws of the jurisdiction
in which the registrant is incorporated, domiciled or legally organized (the
registrant&#8217;s &#8220;home country&#8221;), or under the rules of the home country exchange on
which the registrant&#8217;s securities are traded, as long as the report or other
document is not a press release, is not required to be and has not been
distributed to the registrant&#8217;s security holders, and, if discussing a material
event, has already been the subject of a Form 6-K submission or other Commission
filing on EDGAR.</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">Indicate
by check mark whether the registrant by furnishing the information contained in
this Form is also thereby furnishing the information to the Commission pursuant
to Rule l2g3-2(b) under the Securities Exchange Act of 1934. Yes <font style="DISPLAY: inline; FONT-WEIGHT: bold;" face="Wingdings">o</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>No <font style="DISPLAY: inline; FONT-WEIGHT: bold;" face="Wingdings">x</font></font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">If &#8220;Yes&#8221;
is marked, indicate below the file number assigned to the registrant in
connection with Rule 12g3-2(b):</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">SIGNATURES</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Pursuant to the requirements of the
Securities Exchange Act of 1934, the registrant has duly caused this report to
be signed on its behalf </font>by the undersigned, thereunto duly
authorized.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">Novogen
Limited</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">(Registrant)</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">/s/&#160;&#160;Ron
Erratt</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">Ronald
Lea Erratt</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">Company
Secretary</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">Date
14 April, 2009</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right" align="justify">&#160;</div>
    <div style="TEXT-ALIGN: right">
      <hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="1">
      <hr style="MARGIN-TOP: -13px; COLOR: #000000" noshade size="4">
    </div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt; TEXT-ALIGN: right">&#160;</div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt; TEXT-ALIGN: right">&#160;</div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">&#160;</div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>
      </div>
    </div>
    <div style="TEXT-ALIGN: right">&#160;</div>
    <div style="TEXT-ALIGN: right">&#160;</div>
    <div style="TEXT-ALIGN: right"><img src="novogenlogo.jpg" alt="Novogen logo"></div>
    <div style="TEXT-ALIGN: right">
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">ASX
&amp; MEDIA RELEASE</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">14
APRIL, 2009</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">MARSHALL
EDWARDS, INC., TO UNDERTAKE ANALYSIS OF OVATURE TRIAL</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">Early
analysis enables extension of current resources to additional
programs</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">Novogen
Limited&#8217;s subsidiary, Marshall Edwards, Inc., (NASDAQ: MSHL) has just made the
following announcement.</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">&#160;(New
Canaan, Connecticut., Sydney, Australia - 14 April, 2009) - Marshall Edwards,
Inc., (NASDAQ: MSHL) today announced that it will be undertaking an un-blinded
analysis of the data from its Phase III international, multicentre clinical
study known as &#8220;Ovature&#8221; (<font style="DISPLAY: inline; FONT-WEIGHT: bold">OVA</font>rian <font style="DISPLAY: inline; FONT-WEIGHT: bold">TU</font>mour <font style="DISPLAY: inline; FONT-WEIGHT: bold">RE</font>sponse).</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">Subject
to ethical and regulatory approvals patients currently enrolled in the trial
will continue their treatment according to the study
protocol.&#160;&#160;However new patient recruitment into the Ovature study will
cease and the available data from the 141 completed and current patients will be
analysed for safety and efficacy outcomes.&#160;&#160;As noted by the
Independent Data Monitoring Committee in its last review, there have been no
significant safety concerns raised todate.&#160;&#160;Data analysis for the
primary endpoint, progression free survival, is expected to be completed within
three months.&#160;&#160;Per the study protocol, the secondary endpoint, overall
survival, cannot be analysed until 18 months after the last patient was
randomised, or sooner if there are no patients surviving.</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">The
Company has decided to assess these data from the Ovature trial at this time, as
the current downturn in the global financial markets makes raising further
equity or debt in the near term to fund the trial through to completion most
unlikely.&#160;&#160;According to the agreement reached with the FDA in a
Special Protocol Assessment, the planned interim analysis of the data can be
scheduled only after 95 events of disease progression and full recruitment of
340 patients.&#160;&#160;However, changes in standards of care over the period
the trial has been in operation and the specific inclusion/exclusion criteria of
the Ovature protocol have slowed patient recruitment rates and, consequently,
the Company has deemed it prudent not to fund the trial to
completion.</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">&#8220;The
determination to conduct an un-blinded analysis of the Ovature data has been
taken to assess the clinical and commercialisation opportunities available for
phenoxodiol and to enable the continuing funding from current resources of the
ongoing Phase I and II programs and release funds to in-license promising and
available compounds,&#8221; said Christopher Naughton, President and CEO of Marshall
Edwards, Inc.&#160;&#160;&#8220;We believe that this oncology focused multi-phase
program will maximise opportunities in the best interests of shareholders and
patients and enhance the value of the Company&#8217;s proprietary flavonoid technology
platform over the medium term.&#8221;</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">Accordingly,
the Company intends to allocate its current funds of approximately $23 million
to completing the Ovature data analysis of 141 patients, pursuing negotiations
for out-licensing phenoxodiol should evidence of efficacy and safety emerge from
the Ovature analysis, maintaining other ongoing phenoxodiol ovarian and prostate
cancer clinical trials, initiating the triphendiol clinical program, and to
in-license further promising anti-cancer compounds:</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div id="FTR">
          <div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
        </div>
        <div id="PN" style="PAGE-BREAK-AFTER: always">
          <div style="WIDTH: 100%; TEXT-ALIGN: center">&#160;</div>
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
          </div>
        </div>
        <div id="HDR">
          <div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>
        </div>
      </div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div>
        <table cellpadding="0" cellspacing="0" id="list" width="100%">
            <tr valign="top">
              <td align="right" style="WIDTH: 36pt">
                <div><font style="DISPLAY: inline; FONT-SIZE: 14pt;" face="Symbol, serif">&#183;&#160;&#160;</font></div>
              </td>
              <td>
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">A
      Phase Ib/IIa study of phenoxodiol in combination with the Sanofi-Aventis
      drug Docetaxel (Taxotere<font style="DISPLAY: inline;" face="Symbol">&#210;</font>) in ovarian cancer
      is continuing at the Yale University School of
  Medicine;</font></div>
              </td>
            </tr>
        </table>
      </div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div>
        <table cellpadding="0" cellspacing="0" id="list" width="100%">
            <tr valign="top">
              <td align="right" style="WIDTH: 36pt">
                <div><font style="DISPLAY: inline; FONT-SIZE: 14pt;" face="Symbol, serif">&#183;&#160;&#160;</font></div>
              </td>
              <td>
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">Also
      at Yale, the Phase II clinical trial of phenoxodiol comparing its safety
      and efficacy in patients with early stage and advanced prostate cancer is
      ongoing;</font></div>
              </td>
            </tr>
        </table>
      </div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div>
        <table cellpadding="0" cellspacing="0" id="list" width="100%">
            <tr valign="top">
              <td align="right" style="WIDTH: 36pt">
                <div><font style="DISPLAY: inline; FONT-SIZE: 14pt;" face="Symbol, serif">&#183;&#160;&#160;</font></div>
              </td>
              <td>
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">Marshall
      Edwards also has the drug candidate triphendiol (NV-196), for which an
      Investigational New Drug Application (IND) has been granted by the FDA,
      allowing clinical trials to commence in the US for pancreatic and bile
      duct cancers.&#160;&#160;In addition, this drug was designated by the FDA
      as an Orphan Drug for treatment of pancreatic cancer, bile duct cancer,
      and late stage melanoma;</font></div>
              </td>
            </tr>
        </table>
      </div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div>
        <table cellpadding="0" cellspacing="0" id="list" width="100%">
            <tr valign="top">
              <td align="right" style="WIDTH: 36pt">
                <div><font style="DISPLAY: inline; FONT-SIZE: 14pt;" face="Symbol, serif">&#183;&#160;&#160;</font></div>
              </td>
              <td>
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">Marshall
      Edwards is currently in advanced negotiations with Novogen Limited to
      in-licence the mTOR inhibitor NV-128, which has shown compelling
      preclinical results to date.</font></div>
              </td>
            </tr>
        </table>
      </div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">&#8220;The
scientific and commercial excitement around the potential of mTOR inhibitors,
and particularly this stand-out compound with dual mTORC1 and mTORC2 inhibition,
has made NV-128 a high priority for the Marshall Edwards&#8217; drug development
program,&#8221; said Professor Bryan Williams, the Chairman of Marshall Edwards,
Inc.&#160;&#160;&#8220;We expect to add NV-128 to our portfolio by obtaining oncology
commercialisation rights and to move ahead quickly with the clinical
program&#8221;.</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">About
Ovature</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">The
Ovature study is a multi-centre international Phase III clinical trial of the
orally-administered investigational drug phenoxodiol in women with advanced
ovarian cancer resistant or refractory to platinum-based drugs, to determine its
safety and effectiveness when used in combination with carboplatin.</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">About
Marshall Edwards, Inc. and Novogen Limited</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">Marshall
Edwards, Inc., is a specialist oncology company focused on the clinical
development of novel anti-cancer therapeutics.&#160;&#160;These derive from a
flavonoid technology platform that has generated a number of novel compounds
characterised by broad ranging activity in laboratory testing against a range of
cancer targets with few side effects.&#160;&#160;The ability of these compounds
to target an enzyme present on the surface of cancer cells, and inhibit the
production of pro-survival proteins within the cancer cell suggests that they
may possess a unique combination of efficacy and safety.&#160;&#160;Marshall
Edwards, Inc., has licensed rights from Novogen Limited (ASX: NRT; NASDAQ: NVGN)
to bring three oncology drugs - phenoxodiol, triphendiol (NV-196) and NV-143 -
to market globally.&#160;&#160;Marshall Edwards, Inc., is majority owned by
Novogen Limited, an Australian biotechnology company that is specialising in the
development of therapeutics based on a flavonoid technology
platform.&#160;&#160;More information on phenoxodiol and on the Novogen group of
companies can be found at www.marshalledwardsinc.com and
www.novogen.com.</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Under
U.S. law, a new drug cannot be marketed until it has been investigated in
clinical trials and approved by the FDA as being safe and effective for the
intended use. Statements included in this press release that are not historical
in nature are "forward-looking statements" within the meaning of the "safe
harbor" provisions of the Private Securities Litigation Reform Act of 1995. You
should be aware that our actual results could differ materially from those
contained in the forward-looking statements, which are based on management's
current expectations and are subject to a number of risks and uncertainties,
including, but not limited to, our failure to successfully commercialize our
product candidates; costs and delays in the development and/or FDA approval, or
the failure to obtain such approval, of our product candidates; uncertainties in
clinical trial results; our inability to maintain or enter into, and the risks
resulting from our dependence upon, collaboration or contractual arrangements
necessary for the development, manufacture, commercialization, marketing, sales
and distribution of any products; competitive factors; our inability to protect
our patents or proprietary rights and obtain necessary rights to third party
patents and intellectual property to operate our business; our inability to
operate our business without infringing the patents and proprietary rights of
others; general economic conditions; the failure of any products to gain market
acceptance; our inability to obtain any additional required financing;
technological changes; government regulation; changes in industry practice; and
one-time events. We do not intend to update any of these factors or to publicly
announce the results of any revisions to these forward-looking
statements.</font></div>
    </div>
  </body>
</html>


</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>novogenlogo.jpg
<DESCRIPTION>NOVOGEN LOGO
<TEXT>
begin 644 novogenlogo.jpg
M_]C_X``02D9)1@`!`0```0`!``#_VP!#``8$!08%!`8&!08'!P8("A`*"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!#`0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P``1"`!"`,\#`2(``A$!`Q$!_\0`
M'``!`0$!`0`#`0````````````<&!0@!`P0"_\0`1A```0,#`@,&`@4'"`L`
M`````0`"`P0%$08A!Q)!$R(Q46&!%'$(%3*1H187(S1T@K$S.%)RL\'1X4)&
M5%9B=9*3HL+2_\0`&@$!``,!`0$```````````````(#!`$%!O_$`#(1``$#
M`@4"!`4"!P````````$``A$#!!(3(3%!47$%%(&A(C)2D<%AL2,S0D/1X?'_
MV@`,`P$``A$#$0`_`/5*(B(B(B(B(B(B^BKJ8Z5L3I7!H?(V,$]2XX`^_"^]
M8OC#/4TG#ZXU=$XMJ*9\,['#H6RL.?P70),*%1^!A=T"VB+/Z$U12:NT[3W.
MD+0]PY9X0<F*0>+3_$>8(6@0B-"NM<'@.;L41$7%)$1$1$1$1$1$1$1$1$1$
M1$1$1$1$1$12'B%Q%O.FM;/H:6*GEM\,<4TC'1DN+3]KO`[;*#WA@DK1;6S[
ME^73W5>1?DM-PI[K;*6OHG\]-41B1A]".OJL;Q8U5<M+TUIDM?89J:GLY.U9
MS=W;PW]5US@T8BH4J+ZM3+;NMZB*8ZLXBUIOCK!HJ@;<KFUQ9)*X]QCAX@#;
M..I)`'JCGANZ[0MWUS#!MOT`_54Y9SB/1FOT%?Z=K>9SJ.1S1ZM;S#\0L74#
MBQ14YJ^VM-86CF=2L8.;'C@;#/EL5VM`:^IM7"HM=RI307B-KFS4S_!X&SN7
M.^W5IW'JN-JC$`=%.M8ORW.:0X<P9A><>'FLJW1E\;64N9*63#*FG)P)69_!
MPZ'_`!*]=V"\45^M%-<K9*):6H;S-/4>;2.A!V(\UXOU/:I+'J&XVR7/-2SN
MC!/4`['W&"J)]'_6#[-J,66KEQ;KB[#`X[1S?Z)'];[)_=\EOK,#AB"^3\-N
MG4:F0_8^Q7IQ$6%L>J+A>>)5WM5*8#9;;&&R.#,N=+L,<W3?FV_X5B+@%]/3
MI.J!Q'`DK=(IQKOB.^UW9MATS0_6E\<>4M`)9&<9Q@;DXW/0=3T7X#'Q9%*:
MKXBTN>!GX4-;S'TSC&?=0-43`U6AMD\M#GD-G:3$JK(I[H'B$^\W*2R:AH?J
MR^1DM[,YY92!D@`^!QOC)SYJA.(:"7$`#<D]%)K@X2%16H/H.PO"(I5=.(MW
MOEVGM?#VV-KG0Y;+6S?R;3G`(W`QL=R=_)?$C.+-,P3MEM%6?$T[6M&/3)`^
M7BH9HX$K1Y%X'QN#3T)U5619_0UQO5SLG;ZDMK;=7-E='V;2>\T>#L;XSOU/
MGU66XA:GU'0:QM5CTTVD=+64YD`G;XN#CUSL,!2+P!B*J9;/?4-,$2)YTT_5
M4E%+^UXK?[/9?^L+>Z:=='62E.H&0,NG*>W;`<LSD^'MA=:Z>%RK0RQ.('L5
MTT46TQQ5N#]7?!7YM.+;+4/I62QQEIC?S$,R<XQMO\\JTKC'A^H7;BUJ6Q`J
M<B418&35=Q;Q?BTV.Q^K7TW:GN=_FY"?'/F%OE(.!V5=2DZG&+D2BC-YH:>Y
M<?Q15L39::>W.CD8[P(,3E9E(I_YQU/^PG^S<JZO'=:;$D%Y'TE?/#6NGTAJ
MNNT5>)3V+W&:W2/.S@23@'U&^/,.7]?2#_4=/_MG_P`KL\8M+R7BRQW:V!S;
MQ:LSPN9]IS1@D#&^1C(]1ZK`\0=3,U9HO3%P#>2H;6]E41_T)!RY]CXCYJI_
MPM+#Z+T;89]9ERW?4.[P=?7]U7^(%TDLNC+O7P9$L4!#"#@ASNZ#[9S[+,<"
M['#;]'Q7-S>:LN)=*Z1P[P9G`;GVSZDK0<3;?)<]!WFF@`,I@[1H]6D.V]=E
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MIIN7]1%0YH.`9.7=H_>V64X602V+AM=-0U>375@FKG.D))(:#RY^9!/NIS8[
MK-=^&%ATG2/'Q%9<WP.V^S&"'[^F7Y_=7H&]6ELND*VTT3.5AHGT\3&[8[F&
MC^"P5!_$,<+ZVU>!9TR_^X03V'^Y^RGW`&SAULKM15K"^X5LSF"5^[N48+CG
MU=G[E6E+^`%U94Z4GMLCP*JBG<3&1@ACMQ\]^8*H+E",`A6>)EWFGAW7VX]E
M(>/EL;1TUMU/1?HJZDG;&Y[-BX>+22/(MQ\B0NOQ6U%)!PPCJ:?FCFNC(HQR
MG!:'MYG;_P!4$>ZY_P!(2XQBP4%FC<365M2U[6MW(:WK[N+0%]O%RQS#A521
MM([6UB%[R/#`;R./_EGV5;Y!?AZ+9;PYMOG;8C';_JU7#6PPZ?T?;Z:)@;-+
M&V>=W5TC@"?NV'LM0L]P_O,%]TC;:N!P+A$V*5N<EDC0`X'W_`A:"0D,<1X@
M%7LC"(V7E7!>:KLS>3*^5)M>5E-;^,^EJJMF9!3QTC^>20X:W)>-S\RNQP7U
M#<]1V"OJ;Q4_$31U;HV'D:WE;R@XV`\UQ.(5NI+MQBTQ0W&!L])-2/#XW9P[
M!>>GJ`J7NQL#AU6^VHY%P^G4X:Z8[<+>MUGIIS@UM]MQ).`!.W_%=]8]G#31
M['M>VQTX<TAP/._8@Y!^TM@KFXOZEAK9.F3/K'X4`T9I>/5>F-9T8:/C&7!T
ME*_P+9!G`SY'P/\`DJ%PAU1)?+));[F[%YMKNPJ&.V<YHV#B#]Q]1ZKB\!?]
M:_\`F)_O7T\1:*HT9K"DUM:8'/II7"&XQ,SN#MS>^W[P!ZJAOP@/'JO3JG/J
M/MG;[M[QMZ_ND_\`..I_V$_V;E75&Z>KAK_I`V^KI7B2GGMPDC<.K3$2%9%9
M2Y[K%>@C+!^D?E%-9;%<W<<X;P*.3ZL;1\AJ-N7FY",?>52D4W-Q0L]*J:4Q
MR"/NB\^<1.']RH-4A^GJ"KJ;75S,J3'`WF;"_F[P(Z#J/0D=%Z#11J4Q4$%7
M6=X^T>7,UGA#N,'P4AO6CM0Z2U#-?-`\L]+.>:HMSSX[Y(`/B/'&.\,E5Y%U
M[`[=5T+AU`G#J#N#L5)GZ]UO5,%-1:(GAK=@Z2;F[,$]=P/XKH\/M!5M#>)=
M1ZKJ6U=\F&0T8+8B1@G/@3C88V`\%2$413UEQE7.O(:64FAH.\;_`'/"+F:E
ML=%J*S5-LN<0DIYFX]6.Z.!Z$+IHK=EA(#A!4%X,:#K[+Q!NLETIY1!;0603
M.9ADSG9`<WS[N3MX9"O2(AU)/5&RUC:?#1`[3/Y4JU;H6[VW4;]3:%F9'6/.
M9Z-Q`$F3EV,[8.,D'KN"OK_.!K7LC3_D+4_'X^WW^S\?+'_LJRBJRX/PF%O%
M[B:!68'1L3,^VZE>C-#7:OU`-3:\E;-<&D.IZ5I!;$1X$XV&.@'4Y.ZJ,\,=
M1!)#.QLD4C2Q['#(<#L05_:*;6!H@*BO</KNQ.XV'`[*-R:0U5H.YS5>B'MN
M%KE)<^AE.X'08SN1T(P?1?K;Q"UC-$Z%FA*OXD=TEW.&Y]V_WJLHH"EA^4PM
M!O14UK,#CUU!]8W4_P""^G;EIS3E5!>*<4\\]296Q\X<0WE`WQ\ER^)-!J"+
MB!9+Y8+0^XBCIG-(R`WF+G9!W'1RJB+N4,(:H>=>:SJY`DSVUT4L_*_B'_N0
MS_O?YK>Z6K;E<+)!47JA%!7.+N>G!SRX)QO\L+K(I!I'*IJ50\0&`=I_RIQP
M<LMRLYU&+G1RTPGKC)$7X[[=]QNMW>+;37BUU5OKH^TIJAAC>WT/4>H\5^Q$
M:T`0E2LZI4S-BH1P\TA>[#Q1IVUE'5OM](R:*.L<W]&6<IY,'IG/AYY5W1%R
MG3#!`5EW=NNGA[QJ!"(B*:RHB(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(
+B(B(B(B(B(B+_]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
